The companies will make use of Genome-Wide SpliceArray (GWSA) platform by Exonhit to study AD molecular markers associated with clinical parameters.
Exonhit’s SpliceArray platform is microarray design that incorporates a specific probe configuration, enabling monitoring of RNA splice variants in humans, mice and rats.
The research will lay emphasis on identifying progression and other biomarkers which can segregate healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD.
Pfizer will provide test samples for the study.
The financial details of the deal have not been disclosed.